{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Number of patients in each response category according to RECIST criteria: Progressive disease (PD): \\>=20% increase in sum of longest diameter (LD) of target lesion(s), taking as reference smallest sum LD recorded since treatment started. Complete response (CR): disappearance of all target lesions. Partial response (PR): \\>=30% decrease in sum of LD of target lesion(s), taking as reference baseline sum LD. Stable disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD.","groups":[{"description":"Cisplatin, Starting dose 30 mg/m2 Dose level -1 20 mg/m2; Irinotecan, Starting Dose 50 mg/m2, Dose level -1 40 mg/m2","id":"OG000","title":"Therapeutic Intervention"}],"paramType":"NUMBER","populationDescription":"Analysis was per protocol (7 patients did not receive a full cycle of treatment, and 1 patient was censored for incomplete records)","reportingStatus":"POSTED","timeFrame":"6 weeks after last chemotherapy treatment","title":"Patient Response","type":"PRIMARY","unitOfMeasure":"participants"}